iCMLf Knowledge Centre

eLearning for Clinicians, Molecular Biologists, & Pathologists

iCMLf Knowledge Center


Diary Dates

Save the date for important iCMLf meetings and programs

Become a member

Become an iCMLf member - help shape our future

Please donate

Support our activities
by donating
Donate here


We thank all our supporters and partners


If you are not a member, please click on "Register". If you have forgotten your password, please click on "Forgot login?" below.

EU e-Privacy Directive

CML Expert Opinions

Highlights from EHA 2017:
2 CML experts give their personal perspectives



Perspectives on new CML studies from
Professor Timothy Hughes
South Australian Health and Medical Research Institute (SAHMRI), University of Adelaide, Royal Adelaide Hospital, Australia

  • Phase II study on dasatinib in children and adolescents with CML-CP
  • 10-year survival results of the German CML IV Study
  • Year 2 results from the British Destiny Study 
  • Initial results from the Before trial: Bosutinib vs. Imatinib in newly diagnosed CML
  • Update on treatment-free remission studies



Comments closed!